Indicated for: hematologic malignancies
Route of administration: oral
Substance: pomalidomide (immunomodulator)
ATC: L04AX06 (Antineoplastic and immunomodulating agents | Immunosuppressants | Other immunosuppressants)
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid live vaccines during treatment if contraindicated.
This medicine may increase the risk of infections.
This medicine may affect fetal development.
Pomalidomide is an immunomodulatory agent used in the treatment of relapsed or refractory multiple myeloma. It works by stimulating the immune system and inhibiting tumor cell growth.
The medication is taken orally, as directed by a doctor, usually once daily in treatment cycles. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.
Patients should be aware of potential side effects, such as anemia, fatigue, or infections. It is important to inform the doctor of any unusual symptoms.
Common side effects include anemia, fatigue, and neutropenia. In rare cases, severe reactions such as deep vein thrombosis or allergic reactions may occur. Patients should be informed of these risks before use.